Prevent & end dependence on addictive medications
Lucid Lane is the only company that is focused on the prevention and reduction of dependence on prescribed medications such as opioids, benzodiazepines, and amphetamines that are prescribed by doctors after an illness. Even though they work well for a short period of time, millions of people are becoming long-term chronic users of these prescribed medications, because doctors do not have a comprehensive and scientific solution to help support patients that need to be weaned and tapered from these medications. Lucid Lane is the only company that is building a comprehensive data-driven AI solution for automating personalized medication taper recommendations. We also collect health data on each patient via our remote patient monitoring features through our mobile app that feeds into our AI engine for determining the medication taper recommendations. Our AI engine also monitors and proactively escalates patients that need help in real-time. We serve chronic pain users of opioids as well as patients who are going through surgery and will be prescribed opioids for pain management post-surgery. We collaborate with providers (pain clinics, surgery centers) to help these patients with medication tapering as well as co-occurring pain and mental health therapy.
Lucid Lane is a data-driven telehealth digital solution that empowers people to prevent and reduce dependence on prescribed addictive medications and live a better, healthier life. Lucid Lane is addressing a substance use/medication dependence problem (which is a $50B TAM for Lucid Lane) that over 50M Americans face annually, costing the economy over $700B in healthcare costs in addition to causing irreparable harm and loss of life. Millions of people are becoming dependent on prescribed medications like opioids, benzodiazepines and amphetamines after an illness. We currently partner with pain clinics, surgery centers and primary care clinics and employers to empower and support chronic pain users as well as naive users who are at risk of becoming dependent on opioids. Just within the surgery channel where we partner with surgery centers, about 15M people are becoming dependent on opioids post-surgery which is costing $37B to the health plans in year 2 after surgery that is preventable. Lucid Lane is the only company building a unique data-driven digital telehealth solution to prevent, and reverse, reliance on addictive medications, while improving their pain and mental health to help people live a better, healthier life. This not only improves patient outcomes but also reduces significant costs out of the healthcare system.
We completed a feasibility trial at the University of Texas-Health Sciences examining postoperative opioid tapering, improvements in behavioral health, and engagement with Lucid Lane among opioid-naive (n=101) and opioid-tolerant (n=49) elective spine surgery patients. Published conference findings from this study demonstrate prevention and reversal of chronic and persistent opioid use, statistically significant improvements in behavioral health, and high engagement compared to other telehealth platforms. We are enrolling patients for two randomized controlled trials (RCT) at MD Anderson Cancer Center (MDACC) and Palo Alto Veterans Affairs hospital (PAVA). MDACC, a parallel-arm RCT, compares postoperative opioid tapering and behavioral health improvements among opioid-tolerant and opioid-naive patients receiving Lucid Lane with similar patients receiving standard care. We will enroll patients (n=272) who are undergoing head/neck, abdominal, and thoracic cancer surgery. Palo Alto Veteran's Affairs (PAVA), a crossover RCT, compares preoperative surgery preparedness and postoperative opioid tapering and behavioral health improvements among opioid-naive veterans who receive Lucid Lane preoperatively to those who receive standard care. We will enroll patients (n=100) undergoing total joint arthroplasty. We also conducted a financial return-on-investment (ROI) study comparing postoperative musculoskeletal outcomes for patients that are prescribed opioids between the Marketscan nationwide claims database and Lucid Lane patients that had completed their trials with comparable profiles (n=63). We considered inpatient hospital admissions (~$32k/event), ER visits (~$3.5k/event), outpatient services (~$400/event), and prescription utilization (~$320/event). Findings indicate that Lucid Lane offers significant ROI over the standard of care.
